Reich K, Kristensen LE, Smith SD, Rich P, Sapin C, Liu Leage S, et al. Efficacy and safety of ixekizumab versus adalimumab in patients with active psoriatic arthritis and moderate-to-severe psoriasis: 52-week results from the randomised SPIRIT-H2H trial. Dermatol Pract Concept [Internet]. 2022 May 2 [cited 2026 May 19];12(2):e2022104. Available from: https://dpcj.org/index.php/dpc/article/view/1936